Cost-Effectiveness of Acalabrutinib Monotherapy Compared with Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-137688
Abstract: Introduction: Acalabrutinib is a highly selective, irreversible, next-generation, Bruton tyrosine kinase inhibitor (BTKi) approved for the treatment of patients with chronic lymphocytic leukemia (CLL). Acalabrutinib and ibrutinib are the only BTKis approved for the treatment… read more here.
Keywords: acalabrutinib monotherapy; treatment; acalabrutinib; cost effectiveness ... See more keywords
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Sign Up to like & getrecommendations! Published in 2019 at "Blood advances"
DOI: 10.1182/bloodadvances.2018030007
Abstract: The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation. Acalabrutinib is a potent, covalent BTK inhibitor with greater selectivity… read more here.
Keywords: intolerant ibrutinib; acalabrutinib monotherapy; ibrutinib; lymphocytic leukemia ... See more keywords
Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7547
Abstract: 7547Background: Acalabrutinib, a highly selective, potent, covalent BTK inhibitor, was assessed as monotherapy in pts with R/R de novo DLBCL. Methods: Eligible pts aged ≥18 y, with ECOG PS ≤2 and confirmed R/R non-germinal center… read more here.
Keywords: acalabrutinib monotherapy; response; dlbcl; monotherapy patients ... See more keywords